Health Catalyst (HCAT) Expected to Announce Quarterly Earnings on Wednesday

Health Catalyst (NASDAQ:HCAT) is anticipated to announce its earnings results after the market closes on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $79.59 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Health Catalyst Price Performance

NASDAQ:HCAT opened at $5.23 on Monday. The business’s 50-day moving average price is $6.24 and its 200 day moving average price is $7.31. The firm has a market cap of $318.25 million, a P/E ratio of -3.87 and a beta of 1.34. Health Catalyst has a 52-week low of $5.20 and a 52-week high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Wall Street Analyst Weigh In

HCAT has been the topic of a number of analyst reports. Royal Bank of Canada dropped their price target on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 15th. Piper Sandler dropped their price target on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 11th. Canaccord Genuity Group dropped their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. KeyCorp raised Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target on the stock in a research note on Wednesday, January 8th. Finally, Citigroup dropped their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.20.

Insider Buying and Selling at Health Catalyst

In other news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the sale, the insider now directly owns 236,950 shares in the company, valued at $2,118,333. The trade was a 3.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Jason Alger sold 19,599 shares of Health Catalyst stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now owns 86,712 shares of the company’s stock, valued at approximately $721,443.84. This represents a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 87,610 shares of company stock valued at $664,043 in the last 90 days. 2.50% of the stock is currently owned by corporate insiders.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.